Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve medication-taking behavior.
Susan dosReis, PhD
Advertisement
Articles by Susan dosReis, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
How Often Do Health Insurers Deny Doctor-Recommended Care?
2
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
3
Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story
4
Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM
5